Aclaris Therapeutics (NASDAQ:ACRS) Sees Large Volume Increase
Aclaris Therapeutics (NASDAQ:ACRS) Sees Large Volume Increase
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) shares saw unusually-strong trading volume on Friday . Approximately 758,008 shares traded hands during mid-day trading, an increase of 107% from the previous session's volume of 366,400 shares.The stock last traded at $17.30 and had previously closed at $16.82.
週五，Aclaris治療公司(納斯達克代碼：ACRS-GET評級)的股票交易量異常強勁。午盤交易中，約有758,008股易手，較前一交易日的366,400股增加107%。該股最新報17.30美元，此前收盤報16.82美元。
Analysts Set New Price Targets
分析師設定新的價格目標
A number of analysts have weighed in on ACRS shares. Stifel Nicolaus started coverage on Aclaris Therapeutics in a research report on Tuesday, December 13th. They issued a "buy" rating and a $29.00 price target for the company. The Goldman Sachs Group started coverage on Aclaris Therapeutics in a research report on Thursday, December 1st. They issued a "buy" rating and a $25.00 price target for the company. SVB Leerink reaffirmed an "outperform" rating on shares of Aclaris Therapeutics in a research report on Tuesday, November 8th. BTIG Research assumed coverage on Aclaris Therapeutics in a research report on Thursday, October 6th. They issued a "buy" rating and a $32.00 price target for the company. Finally, StockNews.com assumed coverage on Aclaris Therapeutics in a research report on Wednesday, October 12th. They set a "sell" rating for the company. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $28.67.
許多分析師都加入了ACRS的股票。Stifel Nicolaus於12月13日星期二在一份研究報告中開始報道Aclaris治療公司。他們對該公司的評級為“買入”，目標價為29.00美元。高盛在12月1日星期四的一份研究報告中開始對Aclaris治療公司進行報道。他們對該公司的評級為“買入”，目標價為25美元。SVB Leerink在11月8日(星期二)的一份研究報告中重申了對Aclaris治療公司股票的“跑贏大盤”評級。BTIG Research在10月6日星期四的一份研究報告中承擔了對Aclaris治療公司的報道。他們對該公司的評級為買入，目標價為32.00美元。最後，StockNews.com在10月12日星期三的一份研究報告中承擔了對Aclaris治療公司的報道。他們為該公司設定了“賣出”評級。一名投資分析師對該股的評級為賣出，六名分析師對該公司的評級為買入。根據MarketBeat的數據，該股目前的共識評級為“適度買入”，共識目標價為28.67美元。
Aclaris Therapeutics Trading Up 3.9 %
Aclaris治療公司股價上漲3.9%
The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -13.55 and a beta of 0.53. The firm has a 50-day moving average of $16.24 and a two-hundred day moving average of $16.06.
該公司的市值為11.7億美元，市盈率為-13.55，貝塔係數為0.53。該公司的50日移動均線切入位16.24美元，200日移動均線切入位16.06美元。
Insider Transactions at Aclaris Therapeutics
Aclaris治療公司的內幕交易
In other news, insider Joseph Monahan sold 5,000 shares of Aclaris Therapeutics stock in a transaction that occurred on Thursday, December 15th. The stock was sold at an average price of $15.88, for a total transaction of $79,400.00. Following the sale, the insider now owns 96,386 shares of the company's stock, valued at approximately $1,530,609.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Aclaris Therapeutics news, Director Neal Walker sold 25,000 shares of Aclaris Therapeutics stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $15.25, for a total transaction of $381,250.00. Following the sale, the director now owns 1,220,763 shares in the company, valued at $18,616,635.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Joseph Monahan sold 5,000 shares of Aclaris Therapeutics stock in a transaction on Thursday, December 15th. The stock was sold at an average price of $15.88, for a total transaction of $79,400.00. Following the sale, the insider now owns 96,386 shares in the company, valued at approximately $1,530,609.68. The disclosure for this sale can be found here. 6.70% of the stock is owned by insiders.
在其他消息方面，內部人士約瑟夫·莫納漢在12月15日星期四的一筆交易中出售了5,000股Aclaris治療公司的股票。該股以15.88美元的平均價格出售，總成交金額為79,400.00美元。出售後，這位內部人士現在擁有該公司96,386股股票，價值約1,530,609.68美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過美國證券交易委員會網站。在Aclaris治療公司的其他消息方面，董事尼爾·沃克在1月3日(星期二)的一筆交易中出售了25,000股Aclaris治療公司的股票。這些股票以15.25美元的平均價格出售，總成交額為381,250.00美元。交易完成後，董事現在擁有該公司1220,763股股份，價值18,616,635.75美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可以通過這個環節。此外，內部人士約瑟夫·莫納漢在12月15日星期四的一筆交易中出售了5,000股Aclaris治療公司的股票。該股以15.88美元的平均價格出售，總成交金額為79,400.00美元。出售後，這位內部人士現在擁有該公司96,386股，價值約1,530,609.68美元。關於這次銷售的披露可以找到這裏。6.70%的股份由內部人士持有。
Institutional Investors Weigh In On Aclaris Therapeutics
機構投資者看好Aclaris治療公司
A number of institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP boosted its stake in Aclaris Therapeutics by 3.4% during the first quarter. Wellington Management Group LLP now owns 5,730,253 shares of the biotechnology company's stock worth $98,789,000 after buying an additional 190,985 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Aclaris Therapeutics by 3.0% during the third quarter. BlackRock Inc. now owns 4,810,298 shares of the biotechnology company's stock valued at $75,714,000 after acquiring an additional 140,382 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Aclaris Therapeutics by 4.2% during the third quarter. Vanguard Group Inc. now owns 2,931,709 shares of the biotechnology company's stock valued at $46,145,000 after acquiring an additional 118,024 shares during the period. Commodore Capital LP lifted its holdings in shares of Aclaris Therapeutics by 4.1% during the second quarter. Commodore Capital LP now owns 2,410,622 shares of the biotechnology company's stock valued at $33,652,000 after acquiring an additional 95,974 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Aclaris Therapeutics by 6.9% during the third quarter. Point72 Asset Management L.P. now owns 1,853,251 shares of the biotechnology company's stock valued at $29,170,000 after acquiring an additional 119,351 shares during the period. Institutional investors and hedge funds own 95.33% of the company's stock.
一些機構投資者最近買賣了該公司的股票。惠靈頓管理集團LLP在第一季度將其在Aclaris治療公司的股份增加了3.4%。惠靈頓管理集團(Wellington Management Group LLP)現在擁有這家生物技術公司5730,253股股票，價值98,789,000美元，上個季度又購買了190,985股。貝萊德股份有限公司在第三季度增持了Aclaris治療公司的股票3.0%。貝萊德股份有限公司在此期間增持了140,382股，目前持有這家生物技術公司4,810,298股股票，價值75,714,000美元。先鋒集團在第三季度增持了4.2%的Aclaris Treateutics股票。先鋒集團目前持有這家生物技術公司2,931,709股股票，價值46,145,000美元，在此期間又收購了118,024股。Commodore Capital LP在第二季度增持了Aclaris Treeutics的股票4.1%。Commodore Capital LP現在擁有這家生物技術公司2,410,622股股票，價值33,652,000美元，在此期間又購買了95,974股。最後，Point72 Asset Management L.P.在第三季度增持了6.9%的Aclaris Treeutics股票。Point72 Asset Management L.P.在此期間額外收購了119,351股，現在擁有1,853,251股這家生物技術公司的股票，價值29,170,000美元。機構投資者和對衝基金持有該公司95.33%的股票。
About Aclaris Therapeutics
關於Aclaris Treeutics
(Get Rating)
(獲取評級)
Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.
Aclaris治療公司經營着一家臨牀階段的生物製藥公司，在美國開發治療免疫性炎症性疾病的新型候選藥物。它通過兩個部門運作：治療和合同研究。治療部門參與確定和開發創新療法，以解決免疫炎症性疾病的重大未得到滿足的需求。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Aclaris Therapeutics (ACRS)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免費獲取StockNews.com關於Aclaris治療公司(ACRS)的研究報告
- 市場回顧周-1/23-1/27
- 為什麼Lucid在一天內飆升了近100%
- 利用這些鐵路股票實現增長和收入
- ASML預計今年芯片需求回升，提振銷售觀點
- KLA公司：在動盪不安的半市場中站穩腳跟
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Aclaris治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Aclaris治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。